Orchestra BioMed Holdings, Inc. (OBIO)
(Delayed Data from NSDQ)
$6.70 USD
+0.02 (0.30%)
Updated Aug 30, 2024 04:00 PM ET
After-Market: $6.71 +0.01 (0.15%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth F Momentum F VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
OBIO 6.70 +0.02(0.30%)
Will OBIO be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for OBIO based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for OBIO
Orchestra BioMed Holdings, Inc. (OBIO) Reports Q2 Loss, Lags Revenue Estimates
Orchestra BioMed Holdings, Inc. (OBIO) Loses -25.35% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
OBIO: What are Zacks experts saying now?
Zacks Private Portfolio Services
Earnings Preview: Fortrea Holdings Inc. (FTRE) Q2 Earnings Expected to Decline
Orchestra BioMed Holdings, Inc. (OBIO) Expected to Beat Earnings Estimates: Should You Buy?
Orchestra BioMed Holdings, Inc. (OBIO) Upgraded to Buy: Here's What You Should Know
Other News for OBIO
OBIO Crosses Above Key Moving Average Level
Orchestra BioMed initiated with bullish view at H.C. Wainwright, here's why
Orchestra BioMed reports Q2 results
Piper Sandler Remains a Buy on Orchestra BioMed Holdings (OBIO)
Orchestra BioMed Reports Second Quarter 2024 Financial Results and Provides a Business Update